公开(公告)号：US20190209560A1

公开(公告)日：2019-07-11

申请号：US16178678

申请日：2018-11-02

Applicant: eFFECTOR Therapeutics, Inc.

Inventor： Siegfried H. Reich ,  Paul A. Sprengeler ,  Stephen E. Webber ,  Alan X. Xiang ,  Justin T. Ernst

IPC: A61K31/506 ,  A61K31/551 ,  A61K31/52 ,  A61K31/519 ,  C07D519/00 ,  C07D495/20 ,  C07D471/04 ,  C07D471/20 ,  C07D471/10 ,  C07D487/04 ,  C07D473/34 ,  C07D491/20

CPC classification number: A61K31/506 ,  A61K31/519 ,  A61K31/52 ,  A61K31/551 ,  C07D471/04 ,  C07D471/10 ,  C07D471/20 ,  C07D473/34 ,  C07D487/04 ,  C07D491/20 ,  C07D495/20 ,  C07D519/00

Abstract: The present invention relates to compounds according to Formula (I): or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4a, R4b, R5, R6, R7, R8, W1, W2, Y and n are as defined herein. Also described are pharmaceutically acceptable compositions of Formula I compounds as well as methods for utilizing the compounds of Formula I and the pharmaceutically acceptable compositions of Formula I compounds as inhibitors of Mnk as well as therapeutics for the treatment of diseases such as cancer.

公开(公告)号：US20190136321A1

公开(公告)日：2019-05-09

申请号：US16160820

申请日：2018-10-15

Applicant: The Regents of The University of California ,  eFFECTOR Therapeutics, Inc.

Inventor： Davide Ruggero ,  Andrew Hsieh ,  Merritt Edlind ,  Kevan M. Shokat ,  James Appleman ,  Steve Worland

IPC: C12Q1/6883 ,  C12Q1/6874 ,  G01N33/50

Abstract: The present invention provides methods of identifying an agent or drug candidate molecule, validating a target, and identifying normalizing therapeutics that modulates translation, such as in an oncogenic signaling pathway, in a biological sample as determined by translational profiling of one or more genes in the biological sample. The present invention also provides diagnostic and therapeutic methods using the translational profiling methods described herein.

公开(公告)号：US20170145026A1

公开(公告)日：2017-05-25

申请号：US15358761

申请日：2016-11-22

Applicant: eFFECTOR Therapeutics, Inc.

Inventor： Justin T. ERNST ,  Siegfried H. REICH ,  Paul A. SPRENGELER ,  Chinh Viet TRAN ,  Garrick Kenneth PACKARD ,  Alan X. XIANG ,  Christian NILEWSKI ,  Theo MICHELS

IPC: C07D491/048 ,  C07D491/20 ,  C07D519/00 ,  C07D498/14 ,  C07D491/16 ,  C07D491/153 ,  C07D333/78 ,  C07D307/93

CPC classification number: C07D491/048 ,  C07D307/93 ,  C07D333/78 ,  C07D491/153 ,  C07D491/16 ,  C07D491/20 ,  C07D498/14 ,  C07D519/00

Abstract: The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. For Formula I compounds X, Y, R1, R2, R3a, R3b, R4a, R4b and R5 are as defined in the specification. The inventive Formula I compounds are inhibitors of eIF4A and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.

公开(公告)号：US20170145009A1

公开(公告)日：2017-05-25

申请号：US15355271

申请日：2016-11-18

Applicant: eFFECTOR Therapeutics, Inc.

Inventor： Paul A. SPRENGELER ,  Seigfried H. REICH ,  Stephen E. WEBBER ,  Justin T. ERNST

IPC: C07D471/04

CPC classification number: C07D471/04 ,  C07D471/10

Abstract: The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula IA or Formula IB, as well as stereoisomers, tautomers or pharmaceutically acceptable salts thereof. For Formula IA and Formula IB compounds A1, A2, A3, A4, W1, W2, Y, X, R1, R2, R3, R4a, R4b, R5a, R5b, R6, R7, R8, R9, R9a, R9b, R10 and subscript n are as defined in the specification. The inventive Formula IA and Formula IB compounds are inhibitors of Mnk and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.

公开(公告)号：US20230071483A1

公开(公告)日：2023-03-09

申请号：US17720529

申请日：2022-04-14

Applicant: eFFECTOR Therapeutics Inc.

Inventor： Justin T. ERNST ,  Siegfried H. Reich ,  Paul A. Sprengeler ,  Chinh Viet TRAN ,  Garrick Kenneth PACKARD ,  Alan X. XIANG ,  Christian NILEWSKI ,  Theo MICHELS

IPC: C07D491/048 ,  C07D307/93 ,  C07D333/78 ,  C07D491/153 ,  C07D491/16 ,  C07D491/20 ,  C07D498/14 ,  C07D519/00

Abstract: The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. For Formula I compounds X, Y, R1, R2, R3a, R3b, R4a, R4b and R5 are as defined in the specification. The inventive Formula I compounds are inhibitors of eIF4A and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.

公开(公告)号：US20220119387A1

公开(公告)日：2022-04-21

申请号：US17484564

申请日：2021-09-24

Applicant: eFFECTOR Therapeutics Inc.

Inventor： Siegfried H. REICH ,  Paul A. Sprengeler ,  Stephen E. Webber ,  Alan X. Xiang ,  Justin T. Ernst ,  Bennett C. Borer ,  Samuel Sperry ,  Jo Ann Z. Wilson

IPC: C07D471/04

Abstract: The present invention provides crystalline solids of 6′-((6-aminopyrimidin-4-yl)amino)-8′-methyl-2′H-spiro[cyclohexane-1,3′-imidazo[1,5-a]pyridine]-1′,5′-dione: The crystalline compounds of the present application are inhibitors of Mnk and finds utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.

公开(公告)号：US11286268B1

公开(公告)日：2022-03-29

申请号：US16916820

申请日：2020-06-30

Applicant: EFFECTOR THERAPEUTICS, INC.

Inventor： Samuel Sperry ,  Alan X. Xiang ,  Justin T. Ernst ,  Siegfried H. Reich ,  Paul A. Sprengeler ,  Mike Shaghafi ,  Theo Michels ,  Christian Nilewski ,  Chinh Viet Tran ,  Garrick Kenneth Packard ,  Alan Grubbs ,  Kaveri Urkalan ,  Takasuke Mukaiyama

IPC: C07D519/00 ,  C07D495/04

Abstract: The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. For Formula I compounds X1, X2, X3, X4, X5, X6, Q, L1, L2, Y, R1, R2, R3, R4, R5, R6, R7, R8 and rings A, B and C are as defined in the specification. The inventive Formula I compounds are inhibitors of eIF4e and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.

公开(公告)号：US11130757B2

公开(公告)日：2021-09-28

申请号：US16661507

申请日：2019-10-23

Applicant: eFFECTOR Therapeutics Inc.

Inventor： Siegfried H. Reich ,  Paul A. Sprengeler ,  Stephen E. Webber ,  Alan X. Xiang ,  Justin T. Ernst ,  Bennett C. Borer ,  Samuel Sperry ,  Jo Ann Z. Wilson

IPC: A61K31/506 ,  A61P35/00 ,  C07D471/04

Abstract: The present invention provides crystalline solids of 6′-((6-aminopyrimidin-4-yl)amino)-8′-methyl-2′H-spiro[cyclohexane-1,3′-imidazo[1,5-a]pyridine]-1′,5′-dione: The crystalline compounds of the present application are inhibitors of Mnk and finds utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.

公开(公告)号：US20210177898A1

公开(公告)日：2021-06-17

申请号：US17025607

申请日：2020-09-18

Applicant: eFFECTOR Therapeutics, Inc.

Inventor： Kevin R. WEBSTER ,  Rajesh SHARMA ,  Gary CHIANG

IPC: A61K35/17 ,  C07K14/74 ,  A61P35/00 ,  C07K14/725 ,  C07K14/73 ,  C07K14/16 ,  C07K14/705 ,  C12N5/0783 ,  C07D471/04 ,  C07D487/04 ,  C07D495/20 ,  C07D491/20 ,  C07D471/20 ,  A61K31/501

Abstract: The present disclosure relates to genetically modified T cells comprising a transgene encoding an engineered antigen specific receptor, wherein expression of an endogenous gene selected from MNK1, MNK2, or both are inhibited in the genetically modified T cell in order to enhance central memory T cell subsets in cellular immunotherapy compositions.

公开(公告)号：US10780119B2

公开(公告)日：2020-09-22

申请号：US15989098

申请日：2018-05-24

Applicant: eFFECTOR Therapeutics, Inc.

Inventor： Kevin R. Webster ,  Rajesh Sharma ,  Gary Chiang

IPC: A61K48/00 ,  C07H21/02 ,  C07H21/04 ,  A61K35/17 ,  C07K14/74 ,  A61P35/00 ,  C07K14/725 ,  C07K14/73 ,  C07K14/16 ,  C07K14/705 ,  C12N5/0783 ,  C07D471/04 ,  C07D487/04 ,  C07D495/20 ,  C07D491/20 ,  C07D471/20 ,  A61K31/501 ,  A61K45/06

Abstract: The present disclosure relates to genetically modified T cells comprising a transgene encoding an engineered antigen specific receptor, wherein expression of an endogenous gene selected from MNK1, MNK2, or both are inhibited in the genetically modified T cell in order to enhance central memory T cell subsets in cellular immunotherapy compositions.